Multivariable prediction of functional outcome after first-episode psychosis: a crossover validation approach in EUFEST and PSYSCAN
- PMID: 39375356
- PMCID: PMC11458815
- DOI: 10.1038/s41537-024-00505-w
Multivariable prediction of functional outcome after first-episode psychosis: a crossover validation approach in EUFEST and PSYSCAN
Abstract
Several multivariate prognostic models have been published to predict outcomes in patients with first episode psychosis (FEP), but it remains unclear whether those predictions generalize to independent populations. Using a subset of demographic and clinical baseline predictors, we aimed to develop and externally validate different models predicting functional outcome after a FEP in the context of a schizophrenia-spectrum disorder (FES), based on a previously published cross-validation and machine learning pipeline. A crossover validation approach was adopted in two large, international cohorts (EUFEST, n = 338, and the PSYSCAN FES cohort, n = 226). Scores on the Global Assessment of Functioning scale (GAF) at 12 month follow-up were dichotomized to differentiate between poor (GAF current < 65) and good outcome (GAF current ≥ 65). Pooled non-linear support vector machine (SVM) classifiers trained on the separate cohorts identified patients with a poor outcome with cross-validated balanced accuracies (BAC) of 65-66%, but BAC dropped substantially when the models were applied to patients from a different FES cohort (BAC = 50-56%). A leave-site-out analysis on the merged sample yielded better performance (BAC = 72%), highlighting the effect of combining data from different study designs to overcome calibration issues and improve model transportability. In conclusion, our results indicate that validation of prediction models in an independent sample is essential in assessing the true value of the model. Future external validation studies, as well as attempts to harmonize data collection across studies, are recommended.
© 2024. The Author(s).
Conflict of interest statement
N.K. received honoraria for talks presented at education meetings organized by Otsuka/Lundbeck. W.W.F. has received grants from Lundbeck and Otsuka and lecture honoraria from Sumitomo-Pharma and Forum Medizinische Fortbildung. S.G. received advisory board/consultant fees from the following drug companies: Angelini, Boehringer Ingelheim Italia, Gedeon Richter-Recordati, Janssen Pharmaceutica NV and ROVI. S.G. received honoraria/expenses from the following drug companies: Angelini, Gedeon Richter-Recordati, Janssen Australia and New Zealand, Janssen Pharmaceutica NV, Janssen-Cilag, Lundbeck A/S, Lundbeck Italia, Otsuka, Recordati Pharmaceuticals, ROVI, Sunovion Pharmaceuticals. B.Y.G. has been the leader of a Lundbeck Foundation Centre of Excellence for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS) (January 2009–December 2021), which was partially financed by an independent grant from the Lundbeck Foundation based on international review and partially financed by the Mental Health Services in the Capital Region of Denmark, the University of Copenhagen, and other foundations. All grants are the property of the Mental Health Services in the Capital Region of Denmark and administrated by them. The other authors declare no competing interests.
Figures
References
-
- Rosen, M. et al. Towards clinical application of prediction models for transition to psychosis: a systematic review and external validation study in the PRONIA sample. Neurosci. Biobehav. Rev.125, 478–492 (2021). - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
